Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery

Cancer

Volumn 82, Issue 1, 1998, Pages 168-175

  Stapleton, Alan M F ^a,c   Zbell, Paul ^a   Kattan, Michael W ^a   Yang, Guang ^a   Wheeler, Thomas M ^b   Scardino, Peter T ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Apoptosis; Immunohistochemistry; Oncogene; Prognosis; Prostatic neoplasms

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; PUNCH BIOPSY; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0031942254     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19980101)82:1<168::aid-cncr21>3.0.co;2-%23     Document Type: Article

References (60)

1. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer [comments]. J Urol 1994;152:1837-42.
2. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy - a multivariate analysis of 721 men with long term follow-up. Am J Surg Pathol 1996;20:286-92.
3. Kattan MW, Stapleton AMF, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79:528-37.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
5. Rogers E, Eastham JA, Ohori M, Sariyuce O, Aihara M, Wheeler TM, et al. Impalpable prostate cancer: clinicopathologic features. Br J Urol 1996;77:429-32.
6. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51.
7. Stapleton AMF, Kattan MW, Eastham JA, Wheeler TM, Scardino PT. Which factors best predict treatment failure after radical prostatectomy (RP) for clinically localized prostate cancer? [abstract 1533]. J Urol 1997;157:391.
8. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-43.
9. Schroeder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MR, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992;4:129-38.
10. Yang G, Stapleton AMF, Wheeler TM, Truong LD, Timme TL, Scardino PT, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 1996;2:399-401.
11. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
12. Hosmer DW Jr., Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
13. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994;54:3273-7.
14. Mirchandani D, Zheng J, Miller GJ, Ghosh AR, Shibata DK, Cote RJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147:92-101.
15. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsular penetration. J Urol 1994;152:1709-13.
16. Moul JW. The clinical relevance of oncogenes and tumor suppressor genes in prostate cancer. Monogr Urol 1995;16: 51-65.
17. Isaacs WB, Bova GS, Morton RA. Molecular biology of prostate cancer progression. Cancer Surv 1995;23:19-32.
18. Thompson TC, Timme TL, Hall SJ, Stapleton AMF. Perspectives on the molecular biology of prostate cancer. In: Vogelzang NJ, Scardino PT, Snipley WU, Coffey DS, editors. Comprehensive textbook of genitourinary oncology. Baltimore: Williams & Wilkins, 1996.
19. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995;55:5408-14.
20. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 1996;156:1511-6.
21. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995;1:1295-300.
22. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106-9.
23. Van Veldhuizen PJ, Sadasivan R, Cherian R, Dwyer T, Stephens RL. p53 expression in incidental prostatic cancer. Am J Med Sci 1993;305:275-9.
24. Brooks JD, Bova S, Ewing CM, Carter BS, Robinson J, Piantadosi S, et al. p53 alterations do not predict recurrence in primary human prostate cancers [abstract 966]. J Urol 1996; 155:552A.
25. Visakorpi T, Kallioniemi O, Heikkinen A, Koivula T, Isol J. Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
26. Effert P, McCoy R, Walther P, Liu E. p53 gene alterations in human prostate carcinoma, J Urol 1993;150:257-61.
27. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, et al. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993;53:3369-73.
28. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
29. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-33.
30. Eastham JA, Stapleton AMF, Gousse AE, Timme TL, Yang G, Slawin KM, et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995;1:1111-8.
31. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer,. J Urol 1995;154:414-21.
32. Thompson TC, Timme TL, Sehgal I, Oncogenes, growth factors and hormones in prostate cancer. In: Dickson RB, Salomon DS, editors. Hormones and growth factors in development and neoplasia. New York: John Wiley & Sons, Inc, in press.
33. Gumerlock PH, Chi S-G, Shi X-B, Voeller HJ, Jacobson JW, Gelmann EP, et al. p53 abnormalities in primary prostate cancer: single-strand conformational polymorphism analysis of complimentary DNA in comparison with genomic DNA. J Natl Cancer Inst 1997;89:66-71.
34. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-33.
35. Gerdes J, Schwab U, Lemke H, Stein H, Mason DY. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
36. Bouzuber N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, et al. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989;59:943-7.
37. Gerdes J, Stein H, Pileri S. Prognostic relevance of tumor-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987;11:448-9.
38. Raymond WA, Leong ASY, Bolt JW, Milios J, Jose JS. Growth factors in human prostate carcinoma determined by Ki-67 immunostaining. J Pathol 1988;156:161-7.
39. Harper ME, Goddard L, Wilson DW, Matanhelia SS, Conn IG, Peeling WB, et al. Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 1992;21:75-84.
40. Gallee MP, Visser-de Jong E, ten Kate FJ, Schroeder FH, Van der Kwast TH. Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J Urol 1989;142:1342-6.
41. Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, Neal DE. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 1992;69:609-13.
42. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995;26:87-93.
43. McLoughlin J, Foster CS, Price P, Williams G, Abel PD. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 1993;72:92-7.
44. Bettencourt M-C, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1966;156:1064-8.
45. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972;22:644-52.
46. Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, Spanidos DA. Rodent fibroblast tumors expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 1987;56:251-9.
47. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097-8.
48. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995;11:199-210.
49. Buttyan R, Sawczuk I, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc proto-oncogene in high grade human prostate cancers. Prostate 1987;11:327-37.
50. Fox SB, Persad RA, Royds J, Kone RN, Silcocks PB, Collins CC. p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants? J Urol 1993;150: 490-4.
51. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, et al. Expression of the c-myc proto-oncogene in human prostate carcinoma and benign prostatic hyperplasia. Cancer Res 1986;46:1535-8.
52. Evan G, Harrington E, Fanidi A, Land H, Amati B, Bennett M. Integrated control of cell proliferation and cell death by the c-myc oncogene [review]. Philos Trans R Soc Lond Biol Sci 1994;345:269-75.
53. Hermeking H, Erik D. Mediation of c-myc-induced apoptosis by p53. Science 1994;265:2091-3.
54. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate carcinoma. Hum Pathol 1994;25:797-801.
55. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G et al. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer 1995;75:522-9.
56. Hockenbury D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
57. Hockenbery DM. bcl-2 in cancer, development and apoptosis. J Cell Sci 1994;18(suppl):51-5.
58. Craig RW. The bcl-2 gene family. Semin Cancer Biol 1995;6: 35-43.
59. Shibata MA, Ward JM, Devor DE, Liu M-L, Green JE. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 1996;56:4894-903.
60. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, et al. Implications of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-80.